Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Healthcare product and device company Abbott Laboratories (NYSE:ABT) missed Wall Street’s revenue expectations in Q4 CY2025 ...

Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

While the pandemic caused some of Abbott's segments to balloon (diagnostics) and others to fall short (medical devices), conditions have largely normalized and Abbott's prospects will again rely ...

Abbott Laboratories (ABT) is back in focus after its fourth quarter 2025 earnings, where revenue of US$11.46b missed Wall ...

Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript January 22, 2026 Abbott Laboratories reports earnings inline ...

Abbott Labs stock drops on sales miss and weak guidance for 2026, analyst cuts price target but maintains rating.

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Snacks are increasingly replacing meals as eating patterns shift. Hartman Group data presented at FoodNavigator's Healthy ...